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oral gavage and collecting all the excreted urine for 24 h. 
All of the animals were euthanized 72 h after drug adminis-
tration and tissue samples were harvested from the jejunum 
and colon.
Results All chemotherapeutics caused significant body 
weight loss and diarrhea. Intestinal permeability to iohexol 
was also increased in all treatment groups and histologi-
cal analysis revealed significant intestinal damage in both 
jejunum and colon. Iohexol permeability correlated with 
the severity of clinical signs of gastrointestinal toxicity and 
with acute colonic injury.
Conclusions Chemotherapeutic drugs, such as 5-fluoro-
uracil, oxaliplatin, and irinotecan, increase intestinal per-
meability to iohexol. Measuring intestinal permeability to 
iohexol could provide a simple marker for assessing chem-
otherapy-induced gastrointestinal toxicity.
Keywords Intestinal permeability · Chemotherapy · 
5-Fluorouracil · Oxaliplatin · Irinotecan
Introduction
Gastrointestinal (GI) toxicity is the most common adverse 
effect of chemotherapy and a cause of a variety of symp-
toms [1, 2]. Symptoms relating to chemotherapy-induced 
GI toxicity (CIGT) such as diarrhea, vomiting, weight loss, 
and infections [2] greatly impact patients’ quality of life 
and may also significantly affect the outcome of the treat-
ment. However, currently no objective methods are avail-
able to assess the severity or occurrence of CIGT in indi-
vidual patients [1].
Chemotherapeutic drugs damage the intestinal mucosa 
by directly affecting the normal cellular turnover of entero-
cytes. However, the pathophysiology of CIGT seems to be 
Abstract 
Purpose Gastrointestinal toxicity is the most common 
adverse effect of chemotherapy. Chemotherapeutic drugs 
damage the intestinal mucosa and increase intestinal per-
meability. Intestinal permeability is one of the key markers 
of gastrointestinal function and measuring intestinal perme-
ability could serve as a useful tool for assessing the severity 
of chemotherapy-induced gastrointestinal toxicity.
Methods Male Sprague–Dawley rats were injected intra-
peritoneally either with 5-fluorouracil (150 mg/kg), oxali-
platin (15 mg/kg) or irinotecan (200 mg/kg). Clinical signs 
of gastrointestinal toxicity were assessed daily by weigh-
ing the animals and by checking for diarrhea. After 48 h, 
intestinal permeability to iohexol was measured in vivo by 
giving the animals 1 ml of 647 mg/ml iohexol solution by 
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a multifactorial process that extends beyond simple epi-
thelial damage [3]. Studies have shown that chemotherapy 
compromises the mucosal barrier function and increases 
intestinal permeability [4–7]. Intestinal permeability (IP) is 
one of the key parameters of normal GI function, and mul-
tiple diseases have shown an association with alterations in 
IP [8, 9]. Measuring IP could therefore be a useful tool to 
objectively assess and predict the severity of CIGT, as well 
as to follow-up treatment safety.
The primary purpose of this study was to examine 
whether the severity of CIGT correlates with IP to iohexol. 
Iohexol is routinely used in medical facilities as a contrast 
medium and has also recently proved to be a reliable and 
sensitive marker for IP examinations [10–13]. The advantage 
of using iohexol as an IP marker against other previously 
used markers is that iohexol is non-radioactive, non-hygro-
scopic, not degraded by intestinal microbiota, well tolerated, 
safe, easily detectable, cost-effective, and readily available in 
medical facilities [10, 11, 14, 15]. Because previous studies 
have mainly examined the effects of a combination of dif-
ferent chemotherapeutics on IP, our secondary aim was to 
clarify how individual drugs affect IP. In addition, to fur-
ther characterize the effects of chemotherapeutic agents, we 
examined the intestinal tissues histologically and measured 
the serum levels of zonulin, an endogenous protein that spe-
cifically and reversibly regulates intestinal permeability [16].
Materials and methods
Ethical statement
The experiment using animals was approved by the National 
Animal Experiment Board (ESAVI/114/04.10.07/2015).
Animals
A total of 48 male Hsd:Sprague–Dawley®™ SD®™ (SD) 
rats were obtained from Harlan (Udine, Italy) at the age 
of 6 weeks. The rats were acclimatized for 18 days before 
entering the study. They were housed under specific path-
ogen-free laboratory conditions using artificial lighten-
ing with a 12-h light/dark cycle (lights on at 6 am) with 
room temperature of 22 ± 2 °C and relative humidity of 
55 ± 15 %. The animals were kept in open stainless steel 
cages (59.5 × 38.0 × 20 cm) with solid bottoms and Aspen 
chips as bedding (Tapvei, Harjumaa, Estonia) in social 
groups of four rats. The animals were fed a rat chow (2018 
Teklad Global 18 % Protein Rodent Diet, Harlan Labora-
tories, Madison, WI, USA) ad libitum and provided free 
access to tap water in polycarbonate bottles.
Experimental protocol
After the 18-day acclimatization time and at the com-
mencement of the study, the rats were 8 weeks old and 
their average body weight was 283 ± 16 g. The animals 
were randomly assigned into four experimental groups 
(Control, 5-fluorouracil, oxaliplatin, and irinotecan, n = 12 
per group). Baseline intestinal permeability was assessed 
in vivo (Measurement of intestinal permeability) after 
which a 1-ml blood sample was collected from the tail vein 
under isoflurane (Vetflurane 1000 mg/g, Virbac, Suffolk, 
UK) anesthesia. The chemotherapeutic drugs were admin-
istered after a 13-day recuperation period, and the rats were 
euthanized following a 3-day (76-h) observation period. 
During the observation period, the animals were weighted 
and evaluated for diarrhea (Diarrhea assessment) daily, and 
intestinal permeability measurement was started 48 h after 
the drug dosing. For euthanasia, the rats were fully anesthe-
tized using isoflurane and subsequently exsanguinated by 
cardiac puncture and by severing of the aorta.
Drug administrations
Rats in the experimental group 5-fluorouracil (5-FU) 
received a single dose of 150 mg/kg 5-fluorouracil (pH 
adjusted to between 8.6 and 9.4 with sodium hydroxide) 
(Accord Healthcare, Middlesex, UK) intraperitoneally 
[17]. The oxaliplatin group received a single intraperito-
neal dose of 15 mg/kg oxaliplatin in a vehicle containing 
tartaric acid and sodium hydroxide as a buffering system 
(pH between 4.0 and 7.0) (Hospira UK, Warwickshire, UK) 
[18]. The Irinotecan group was injected intraperitoneally 
with a 200 mg/kg dose of irinotecan in sorbitol/lactic acid 
buffer (45 mg/ml of sorbitol, 0.9 mg/ml lactic acid, pH 3.5) 
(Hospira UK, Warwickshire, UK) [19]. Immediately prior 
to irinotecan injection, the rats were given 0.01 mg/kg atro-
pine (Leiras, Espoo, Finland) subcutaneously to reduce the 
irinotecan-induced cholinergic reaction. The control group 
received a single intraperitoneal injection of 0.9 % saline 
solution. All injections were administered under isoflurane 
anesthesia.
Diarrhea assessment
After the administration of the drugs, the animals were 
checked daily for diarrhea. The severity of diarrhea was 
scored accordingly as 0, no diarrhea; (1) mild diarrhea 
(staining of anus, moist surface of feces); (2) moderate 
diarrhea (staining of top of legs and lower abdomen, vis-
cous fecal matter); (3) severe diarrhea (staining over legs 
and higher abdomen, pasty fecal matter) [20].
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Blood sampling
The blood samples were collected in serum separation 
tubes (VenoSafe™ Clot Act. (Z), Terumo Europe, Leuven, 
Belgium) and centrifuged at 1500g for 10 min. The sepa-
rated serum was collected and stored in −80 °C for later 
analysis.
Measurement of intestinal permeability
The intestinal permeability was assessed with iohexol 
(Omnipaque 300™, 647 mg iohexol/ml, GE Healthcare, 
Oslo, Norway). The rats were weighed and given 1 ml of 
647 mg/ml iohexol solution by oral gavage. After adminis-
tration, the animals were immediately placed in individual 
metabolic cages for urine collection. After 24 h, the amount 
of collected urine was measured and stored in -18 °C for 
later analysis. Samples were discarded if fecal contamina-
tion or incomplete urine collection was observed.
Analysis of iohexol
The urine concentration of iohexol was measured by 
enzyme-linked immunosorbent assay (ELISA) according 
to the manufacturer’s instructions (BioPAL Inc., Worcester, 
MA, USA). The percentage of excreted iohexol was calcu-
lated using the following equation:
Iohexol (%) = amount of iohexol excreted in urine after 
24 h (mg)/amount of administered iohexol (mg) × 100
Tissue collection
Following euthanasia, the abdomen was opened and the 
entire intestine was removed. Tissue samples (1 cm) were 
taken from the middle section of the jejunum and colon. 
The samples were opened and flushed free of any intestinal 
content with cold PBS. For histological analysis, the tissue 
samples were fixed in 10 % neutral buffered formaldehyde 
(Sigma-Aldrich, St. Louis, MO, USA) for 24–48 h, embed-
ded in paraffin, cut into at 4-μm thick sections, and stained 
with hematoxylin–eosin (HE).
Analysis of serum zonulin
The serum concentration of zonulin was measured by 
ELISA according to the manufacturer’s instructions (Blue-
Gene, Shanghai, China).
Histological analysis
Jejunum and colon samples were evaluated and mucosal 
lesions graded separately. As a basis for grading we 
employed a system originally developed to diagnose 
gastrointestinal inflammation-related changes in dogs and 
cats [21], however, modifying it substantially and applying 
a four-tier scale for grading: minimal (1), mild (2), mod-
erate (3) and marked (4). In jejunal samples, we assessed 
five change categories: villous stunting, villous epithelial 
injury, crypt hyperplasia, crypt epithelial injury, and leu-
kocyte infiltration in lamina propria; in the colon compara-
ble five categories were analyzed: surface epithelial injury, 
crypt hyperplasia, crypt dilatation and distortion, crypt epi-
thelial injury, and leukocyte infiltration in lamina propria. 
In addition, separate evaluations were made for Paneth cell 
injury in the jejunum and crypt loss (atrophy) in the colon. 
Finally, the histopathological grades of jejunal villous epi-
thelial injury, villous stunting, crypt epithelial injury, and 
Paneth cell injury were combined and averaged to obtain a 
general measure (score) of acute jejunal injury; correspond-
ingly, for acute colonic injury, the histopathological grades 
of surface epithelial injury, crypt epithelial injury, and 
crypt loss were combined and averaged. Histopathological 
assessment was done in a partly blinded manner. The reader 
of the slides (JL) was aware of the experimental design and 
which animals were in the same group but was unaware of 
the group identities. Criteria for grading and rationale for 
the selection of the change categories employed in scor-
ing of the acute jejunal and colonic histological injuries are 
detailed in supplementary data (Online Resource 1).
Data analysis
Normality of the datasets was tested using Kolmogorov–
Smirnov test. Based on this analysis, differences in iohexol 
permeability, body weight change, diarrhea scores, and his-
tological scores were analyzed using Kruskal–Wallis test 
and if global p < 0.05, Mann–Whitney U test was used to 
calculate the statistical differences between the groups. The 
results are expressed as medians ± interquartile range. All 
correlations between variables were calculated as Spear-
man’s rho correlation coefficients. Statistical calculations 
were made by PASW Statistics software version 18.0.2 
(IBM, Armonk, NY, USA). GraphPad Prism 5 (GraphPad 
Software Incorporated, La Jolla, CA, USA) was used to 
create the figures. Histological images were obtained with 
Axio Imager. A2 microscope (Carl Zeiss, Goettingen, Ger-
many) using a 20× objective. Data were deemed signifi-
cant when p < 0.05.
Results
Drug response
All drugs caused significant body weight loss compared to 
the Control group (p < 0.001) (Fig. 1a, b). The irinotecan 
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group lost 16.0 ± 3.5 % of their body weight during the 
experiment (72 h), which was significantly (p < 0.001) 
more than the rats in groups oxaliplatin (11.6 ± 3.4 %) and 
5-FU (6.6 ± 2.3 %) (Table 1). There were no differences 
in body weight between the groups at the start of experi-
ment. In the oxaliplatin group, two rats failed to show any 
response to the drug and showed similar characteristics in 
every category as the animals in the Control group. This is 
most likely due to some problem in the drug administration 
and they were thus removed from all data analyses. Dur-
ing the experiment, 50 % (6/12) of the 5-FU group devel-
oped mild diarrhea. In the oxaliplatin group, 10 % (1/10) 
had mild diarrhea, 80 % (8/10) moderate, and 10 % (1/10) 
severe diarrhea. In the irinotecan group, 8 % (1/12) devel-
oped mild diarrhea, 25 % (3/12) moderate, and 67 % (8/12) 
severe diarrhea. No diarrhea was observed in the control 
group (Fig. 2).
Permeability to iohexol
Iohexol permeability was significantly (p < 0.001) lower in 
the Control group (0.47 ± 0.18 %) than in the treatment 
groups. Rats in the 5-FU group (1.55 ± 1.46 %) exhibited 
significantly (p < 0.05) lower iohexol permeability com-
pared to the rats in the oxaliplatin group (2.61 ± 1.45 %). 
Iohexol permeability was significantly (p < 0.001) 
increased in the irinotecan group (8.07 % ± 8.90) com-
pared to the other groups (Fig. 3; Table 1). A total of four 
samples were discarded because of fecal contamination: 
one from the 5-FU group and three from the irinotecan 
group. There were no differences in the baseline intestinal 
permeability between the groups (data not shown).
a b
Fig. 1  Effects of 5-fluorouracil, oxaliplatin, and irinotecan on 
the animals’ body weight. a Median body weights (g) in differ-
ent treatment groups from the beginning of the study (Day -13) to 
the end (Day 3). The drugs were administered on Day 0. b All the 
studied chemotherapeutics caused significant body weight (%) loss 
already in 24 h compared to the Control group (n = 12). Irinote-
can (n = 12) caused a significantly more severe loss in body weight 
than oxaliplatin (n = 10) and 5-fluorouracil (n = 12) in 72 h. How-
ever, 5-fluorouracil induced a significantly milder body weight loss 
than oxaliplatin. Line graphs show median with interquartile range. 
(***p < 0.001 compared to all other groups; **p < 0.01 between 
groups)
Table 1  Intestinal permeability to iohexol (% of administered 
iohexol) and body weight change in different treatment groups 72 h 
after drug administration
Results are expressed as medians ± interquartile ranges
a Statistically significant difference between groups (p < 0.05)
b Statistically significant difference between groups (p < 0.001)
Group Iohexol permeability (%) Δ Body weight (%)
Control 0.47 ± 0.18b 0.88 ± 2.6b
5-Fluorouracil 1.55 ± 1.46b,a −6.6 ± 2.3b
Oxaliplatin 2.61 ± 1.45b,a −11.6 ± 3.4b
Irinotecan 8.07 ± 8.90b −16.0 ± 3.5b
Kruskal–Wallis p < 0.001 p < 0.001
Fig. 2  Incidence of diarrhea (%) in different treatment groups 72 h 
after drug administration. Score 0 = no diarrhea; Score 1 = mild 
diarrhea (staining of anus, moist surface of feces); Score 2 = moder-
ate diarrhea (staining of top of legs and lower abdomen, viscous fecal 
matter); Score 3 = severe diarrhea (staining over legs and higher 
abdomen, pasty fecal matter) [20]. (n = 12 in all groups, except in 
oxaliplatin where n = 10)
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Correlations between diarrhea scores, body weight 
change, and permeability to iohexol
There was an inverse correlation between body weight 
change and permeability to iohexol (Spearman’s rho: 
−0.873, p < 0.001) (Fig. 4a). Diarrhea scores correlated 
positively with iohexol permeability (Spearman’s rho: 
0.815, p < 0.001) (Fig. 4b) and inversely with body weight 
change (Spearman’s rho: −0.883, p < 0.001) (Fig. 4c).
Serum zonulin
No differences were observed in serum zonulin concentra-
tions between groups (data not shown).
Histological analysis
After parenteral application, all chemotherapeutics caused 
significant histological changes in the jejunum (Table 2) 
and colon (Table 3); the changes are summarized in 
Table 4 and typical alterations depicted in Fig. 5. In the 
jejunum, the height of the villi was significantly decreased 
compared to controls (p < 0.001). Moderate-to-marked 
villous epithelial injury was observed in the oxaliplatin 
group, whereas irinotecan and 5-FU caused mainly mild 
epithelial damage. Oxaliplatin also caused significantly 
more severe epithelial injury in the crypts than irinote-
can and 5-FU (p < 0.001 and p = 0.002, respectively). 
Mild-to-moderate crypt hyperplasia was observed in the 
irinotecan group which was significantly more promi-
nent compared to oxaliplatin and 5-FU groups (p = 0.015 
and p = 0.001, respectively). Oxaliplatin caused a sig-
nificant increase in lamina propria leukocytes compared 
to irinotecan and 5-FU (both p < 0.001). Lamina propria 
leukocytes were also present in the Irinotecan and 5-FU 
groups although the increase caused by irinotecan was sig-
nificantly milder compared to 5-FU (p = 0.003). Oxalipl-
atin and 5-FU caused mild-to-moderate Paneth cell injury 
which was significantly (p < 0.001) different from irinote-
can that did not cause any observable damage to Paneth 
cells. The histological score for acute jejunal injury was 
significantly (p < 0.001) larger in the oxaliplatin group 
(3.7 ± 0.5) than in the other groups (Fig. 5a). Acute jeju-
nal injury was also significantly (p < 0.05) more evident 
in the 5-FU group (2.6 ± 1.0) than in the irinotecan group 
(2.0 ± 0.2) (Fig. 6a).
Fig. 3  Intestinal permeability to iohexol (% of administered iohexol) 
in different treatment groups 72 h after drug administration. All the 
studied chemotherapeutics significantly increased iohexol perme-
ability compared to the Control group (n = 12). Irinotecan (n = 9) 
significantly increased iohexol permeability compared to oxaliplatin 
(n = 10) and 5-fluorouracil (n = 11). Iohexol permeability was also 
significantly lower in the 5-fluorouracil group compared to the oxali-
platin group. Box plots show median with upper and lower quartiles. 
Whiskers show minimum and maximum. (*p < 0.05; ***p < 0.001)
a b c
Fig. 4  Spearman’s correlations between body weight change and 
iohexol permeability (a), iohexol permeability and diarrhea score 
(b), and body weight change and diarrhea score (c). Iohexol perme-
ability correlated inversely with body weight change (Spearman’s 
rho = −0.873, p < 0.001) and positively with diarrhea score (Spear-
man’s rho = 0.815, p < 0.001). There was also a significant inverse 
correlation between body weight change and diarrhea score (Spear-
man’s rho = −0.883, p < 0.001)
868 Cancer Chemother Pharmacol (2016) 78:863–874
1 3
In the colon, mild-to-moderate surface epithelial injury 
was observed in the irinotecan and oxaliplatin groups and 
the degrees of injury were significantly larger than in the 
5-FU group (p = 0.001 and p = 0.011, respectively). Iri-
notecan caused also significantly more damage in the crypt 
epithelium than 5-FU (p = 0.001). Mild crypt hyperplasia 
Table 2  Histopathological grades of the analyzed change categories in the jejunum
Results are expressed as means ± standard deviations. 1 = minimal, 2 = mild, 3 = moderate, 4 = marked
a Statistically significant difference between groups (p < 0.05)
b Statistically significant difference between groups (p < 0.01)
c Statistically significant difference between groups (p < 0.001)
Group Villous stunting Villous epithelial injury Crypt hyperplasia Crypt injury Paneth cell injury Lamina propria 
Leukocytes
Control
5-Fluorouracil 2.8 ± 1.1a 2.3 ± 1.3a 0.75 ± 1.1b 2.9 ± 0.79a 2.3 ± 0.49a,c 2.9 ± 0.51b,c
Oxaliplatin 3.6 ± 0.52a,b 3.5 ± 0.70a,b 1.5 ± 1.1a 4.0 ± 0.0a,c 2.8 ± 0.42a,c 4.0 ± 0.0c
Irinotecan 2.7 ± 0.65b 2.3 ± 0.45b 2.5 ± 0.52a,b 2.7 ± 0.49c 0c 1.6 ± 1.2b,c
Kruskal–Wallis p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
Table 3  Histopathological grades of the analyzed change categories in the colon
Results are expressed as means ± standard deviations. 1 = minimal, 2 = mild, 3 = moderate, 4 = marked
a Statistically significant difference between groups (p < 0.05)
b Statistically significant difference between groups (p < 0.01)
c Statistically significant difference between groups (p < 0.001)
Group Surface epithelial injury Crypt hyperplasia Crypt dilatation and 
distortion
Crypt injury Crypt atrophy Lamina propria 
Leukocytes
Control
5-Fluorouracil 1.3 ± 0.62a,c 1.7 ± 0.78 2.3 ± 0.65 1.8 ± 0.45b 0b 0.33 ± 0.78c
Oxaliplatin 1.9 ± 0.87a 2.0 ± 0.0a 1.8 ± 0.63 2.2 ± 0.63 0b 0.80 ± 1.0a
Irinotecan 2.3 ± 0.49c 1.0 ± 1.0a 2.2 ± 0.39 2.7 ± 0.65b 0.83 ± 1.0b 1.9 ± 0.67a,c
Kruskal–Wallis p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
Table 4  Summary of the histopathological changes
LCs leukocytes
Group Jejunum Colon
5-Fluorouracil Moderate villous stunting
Mild epithelial injury
Minimal crypt hyperplasia
Moderate crypt injury
Mild-to-moderate Paneth cell injury
Moderate infiltration of LCs to lamina propria
Minimal surface epithelial injury
Mild crypt hyperplasia
Mild crypt dilatation and distortion
Mild crypt injury
No observable crypt atrophy
No to minimal infiltration of LCs to lamina propria
Oxaliplatin Marked villous stunting
Moderate-to-smarked epithelial injury
Mild crypt hyperplasia
Marked crypt injury
Mild-to-moderate Paneth cell injury
Marked infiltration of LCs to lamina propria
Mild-to-moderate surface epithelial injury
Mild crypt hyperplasia
Mild crypt dilatation and distortion
Mild crypt injury
No observable crypt atrophy
Minimal infiltration of LCs to lamina propria
Irinotecan Moderate villous stunting
Mild epithelial injury
Mild-to-moderate crypt hyperplasia
Moderate crypt injury
No Paneth cell injury
Mild infiltration of LCs to lamina propria
Mild-to-moderate surface epithelial injury
Mild crypt hyperplasia
Mild crypt dilatation and distortion
Moderate crypt injury
Minimal crypt atrophy
Mild infiltration of LCs to lamina propria
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was observed in all of the treatment groups. Irinotecan 
increased lamina propria leukocytes significantly more than 
oxaliplatin and 5-FU (p = 0.010 and p < 0.001, respec-
tively). Crypt atrophy was only observed in the irinotecan 
group. The histological score for acute colonic injury was 
significantly higher in the irinotecan group (1.9 ± 1.0) than 
in the oxaliplatin group (1.4 ± 0.6, p < 0.05) and in the 
5-FU group (1.0 ± 0.5, p < 0.001) (Fig. 6b). Acute colonic 
injury was also significantly (p = 0.018) more prominent in 
the oxaliplatin group than in the 5-FU group (Fig. 5b).
Correlations between permeability to iohexol, 
histological scores, and body weight change
Iohexol permeability and histological score for acute 
colonic injury (Fig. 7c) showed a significant positive 
Fig. 5  Representative images 
of the histological findings of 
jejunum (left panel) and colon 
(right panel) in each group: 
control (a, b), 5-FU (c, d), 
oxaliplatin (e, f), and irinotecan 
(g, h). Jejunal samples of the 
5-FU (c) and irinotecan (g) 
groups exhibit moderate dam-
age with fused and shortened 
villi and crypt distortion. In the 
oxaliplatin group, the jejunal 
(e) surface epithelium and 
crypts are markedly damaged; 
surface epithelium lost and 
crypts collapsed. In the colon, 
the 5-FU (d) and oxaliplatin 
(f) groups display minimal to 
mild changes. In the Irinotecan 
group, the surface epithelium 
of the colon (h) is mildly to 
moderately injured while the 
crypts are moderately damaged 
and partly lost
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a b
Fig. 6  Calculated scores for acute jejunal (a) and colonic (b) injury. 
Oxaliplatin (n = 10) caused significantly more severe acute injury 
in the jejunum than 5-fluorouracil (n = 12) and irinotecan (n = 12). 
Irinotecan-induced significantly milder damage in the jejunum than 
5-fluorouracil. However, in the colon, irinotecan caused the most 
severe damage. Colonic injury was also more prominent in the Oxali-
platin group than in the 5-fluorouracil group. Box plots show median 
with upper and lower quartiles. Whiskers show minimum and maxi-
mum. (*p < 0.05; ***p < 0.001)
a b
C d
Fig. 7  Spearman’s correlations between iohexol permeability and 
acute jejunal injury score (a), body weight change and acute jejunal 
injury score (b), iohexol permeability and acute colonic injury score 
(c), and body weight change and acute colonic injury score (d). Acute 
colonic injury scores correlated positively with iohexol permeability 
(Spearman’s rho = 0.450, p < 0.013) and inversely with body weight 
change (Spearman’s rho = −0.688, p < 0.001). No significant corre-
lations were observed between acute jejunal injury score and iohexol 
permeability (p = 0.091) and between acute jejunal injury score and 
body weight change (p = 0.108)
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correlation (Spearman’s rho = 0.450, p = 0.013). Con-
versely, a significant inverse correlation was observed 
between acute colonic injury and body weight change 
(Spearman’s rho = -0.688, p < 0.001) (Fig. 7d). Acute 
jejunal injury showed no significant correlation either with 
iohexol permeability or with body weight change (Fig. 7a, 
b). The control group was omitted from this correlation 
analysis because their histological scores were all zero and 
thus they skewed the correlation toward the control values.
Discussion
The aim of our study was to investigate whether intestinal 
permeability to iohexol accurately reflects the severity of 
chemotherapy-induced gut toxicity. Previous studies have 
shown that chemotherapeutic agents can increase intestinal 
permeability [4, 22–24], but the effects of individual agents 
remain relatively unknown.
Results from our study show that 5-FU, oxaliplatin, 
and irinotecan can all damage the intestinal mucosa and 
increase intestinal permeability to iohexol. In addition, 
iohexol permeability reflected the severity of gut toxicity 
observed as body weight loss, diarrhea symptoms, and his-
tological injury in the colon. These interesting findings raise 
the question whether iohexol permeability could be used as 
a marker of CIGT in the clinical practice. Halme et al. [13] 
have previously concluded that intestinal permeability to 
iohexol is an accurate marker of disease activity in patients 
with inflammatory bowel disease (IBD). Because IBDs and 
CIGT share similar clinical features, iohexol permeability 
could also serve as a tool to objectively assess CIGT in 
patients. Some evidence already exists that increased intes-
tinal permeability could correlate with the severity of CIGT 
[5–7, 22, 25]. For example, Russo et al. [5] found that a 
chemotherapy regimen consisting of 5-FU, epirubicin, 
and cyclophosphamide increased intestinal permeability 
(measured as lactulose/mannitol ratio) significantly more 
in patients who were suffering from chemotherapy-induced 
diarrhea compared with patients who did not develop diar-
rhea. Melichar et al. [7] studied the effects of paclitaxel and 
platinum on intestinal barrier function and found that those 
patients that developed the most severe diarrhea had also 
the largest increase in intestinal permeability to different 
sugar probes. Interestingly, they also found that pre-chem-
otherapy intestinal permeability values were elevated in 
patients with the most severe diarrhea grades [7]. This indi-
cates that measuring intestinal permeability before chemo-
therapy could possibly identify those patients that are the 
most susceptible to CIGT and thus allow clinicians adjust 
their dosing accordingly. However, other studies have not 
found any differences in pre-chemotherapy intestinal per-
meability values and the risk of severe CIGT [5, 23]. Thus, 
the association between the risk of CIGT and intestinal per-
meability requires more research.
The exact molecular mechanisms by which chemothera-
peutic agents cause gut toxicity remain unknown. Recent 
preclinical studies have focused on the role of tight junc-
tions in CIGT. Tight junctions are protein complexes that 
connect adjacent epithelial cells together and limit solute 
flux through the paracellular space [26]. Solutes can cross 
the epithelial barrier either paracellularly by passive diffu-
sion through tight junctions or transcellularly by crossing 
through the cell membranes. Usually, the paracellular path-
way is more permeable than the transcellular route mak-
ing tight junctions key regulators of intestinal permeability 
[26]. Intestinal permeability is also regulated by zonulin. 
Zonulin is a physiological regulator of tight junctions and 
high serum concentrations of zonulin have been associ-
ated with increased intestinal permeability [27]. Previously, 
Russo et al. [5] studied the serum zonulin concentrations of 
patients receiving chemotherapy and did not observe any 
changes during the treatment even though they observed an 
increase in intestinal permeability. Similarly, we also did not 
observe any differences in zonulin concentrations between 
the groups despite the increased intestinal permeability to 
iohexol. Because iohexol permeates the epithelia passively 
through the tight junctions [15], these findings indicate that 
chemotherapeutics affect tight junctions through mecha-
nisms that are not zonulin-dependent. Studies have shown 
that chemotherapeutics can affect the expression of tight 
junctional proteins. Wardill et al. [28] showed that irinote-
can decreases the expression of tight junctional proteins in 
the small and large intestine. However, they did not exam-
ine whether this change in protein expression increases 
intestinal permeability. Nakao et al. [29] observed a simi-
lar irinotecan-induced decrease in tight junctional protein 
expression in the intestine. They were also able to show 
that irinotecan treatment decreases transepithelial resist-
ance in the colon suggesting increased intestinal perme-
ability to macromolecules [29]. These findings together 
with our results imply that the irinotecan-induced gut tox-
icity is at least in part mediated by tight junctional dam-
age leading to increased intestinal permeability. This can 
also be the case regarding 5-FU and oxaliplatin although 
little is known about their effects on tight junctional pro-
teins. 5-FU increases intestinal permeability to technetium-
labeled diethylene-triamine-pentaacetate (Tc-99 m-DTPA) 
in mice [30, 31] and to chromium-labeled ethylenediamine-
tetraacetate (51Cr-EDTA) in humans [6, 25] but the role of 
tight junctional protein expression in this process remains 
uncharacterized. The data regarding the effects of oxalipl-
atin are even scarcer and to our knowledge this is the first 
study to show that oxaliplatin causes a significant increase 
in intestinal permeability. However, more research is needed 
to elucidate the role of tight junctions behind these changes.
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The histopathological findings in our study show sig-
nificant mucosal damage expressing as villous stunting and 
crypt destruction. These results are in line with previous 
studies [18, 28, 32]. Overall, the histopathological altera-
tions were more pronounced in the small intestine than in 
the colon, although the grading between the two sites is 
not directly comparable. However, intestinal permeabil-
ity to iohexol and the change in body weight correlated 
with the degree of acute colonic injury. This suggests that, 
in addition to the clinical signs of CIGT, increased intes-
tinal permeability to iohexol can also reflect the extent of 
chemotherapy-induced pathological changes in the colon. 
This was not the case in the small intestine where iohexol 
permeability did not correlate with the degree of acute 
intestinal injury in the jejunum. This could be due to our 
study setting where we collected all the excreted urine 
in 24 h and not multiple samples during the day. There-
fore, we cannot distinguish between small intestinal and 
colonic iohexol permeability and may only see the differ-
ence in the permeability of the whole intestine. Notably, in 
human IBD iohexol permeability was highest in patients 
with moderate-to-severe disease activity in the colon 
[13]. Our histopathological findings also reveal that there 
seems to be some differences in the mechanism of toxic-
ity between the studied chemotherapeutics. For example, 
oxaliplatin caused more severe damage in the small intes-
tine than 5-FU and irinotecan. Irinotecan on the other hand 
affected the large intestine more severely than oxaliplatin 
and 5-FU, even resulting to minimal mucosal atrophy (loss 
of crypts) in the colon. The irinotecan-induced colonic 
damage is probably due to microbial β-glucuronidase that 
converts the glucuronidated irinotecan metabolite 7-ethyl-
10-hydroxycamptothecin (SN-38G) back to its toxic form 
SN-38 [33]. SN-38 is the active metabolite of irinotecan 
that is largely responsible for its toxicity. This added toxic-
ity of irinotecan could also explain why we observed the 
most severe clinical signs of CIGT and increased intestinal 
permeability in the irinotecan group. There were also some 
differences in crypt damage between the groups. We killed 
all the animals after 72 h, and at this time point jejunal 
crypt damage was the most severe in the oxaliplatin group. 
However, at the same time the irinotecan group expressed 
extensive crypt hyperplasia. Crypt hyperplasia is usually 
a follow-up reaction to crypt damage which indicates that 
the most severe crypt damage happened earlier in the iri-
notecan group. This is supported by the findings of Wardill 
et al. [28] who reported the most severe irinotecan-induced 
jejunal crypt damage between 48 and 72 h. Interestingly, 
5-FU and oxaliplatin caused significantly more leukocyte 
infiltration in the jejunal lamina propria than irinotecan. 
This effect was reversed in the colon where irinotecan-
induced leukocyte infiltration in the lamina propria. These 
findings highlight the role of inflammatory reaction in 
CIGT. Reports have shown that proinflammatory cytokines 
contribute to the pathophysiology of CIGT [34–36] and 
researchers have had some success alleviating CIGT with 
immunosuppressive substances [18, 37, 38]. Given that 
proinflammatory cytokines can disrupt the mucosal barrier 
function and increase intestinal permeability [39], the inter-
play between the two is probably one of the key factors in 
the pathophysiology of CIGT.
In conclusion, our results show that 5-FU, oxaliplatin, 
and irinotecan increase in vivo intestinal permeability 
to iohexol. Iohexol permeability correlated with clinical 
manifestations of CIGT such as diarrhea severity and body 
weight loss, and with histopathological scoring for acute 
injury in the colon. Thus, measuring iohexol permeabil-
ity shows promise to potentially provide a simple marker 
for objectively assessing the severity of CIGT and helping 
to understand the relationship between the pathophysiol-
ogy of CIGT and intestinal permeability. However, further 
research is needed to refine the methodology and validate 
its usefulness for clinical applications.
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